|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.77/-1.10
|
企業價值
291.58M
|
資產負債 |
每股賬面淨值
1.18
|
現金流量 |
現金流量率
--
|
損益表 |
收益
755.00K
|
每股收益
0.23
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/05/17 02:21 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications. |